摘要
Aims: Although embolic protection devices reduce complications during saphenous vein graft(SVG) stenting, adverse events still occur in ～10%of patients. IIb/IIIa antagonists have not been proven effective during SVG intervention. We hypothesized that adjunctive use of these agents might enhance the efficacy of embolic protection devices. Methods and results: In the prospective, multicentre FilterWire EX Randomized Evaluation trial, 651 patients undergoing SVG stenting were randomized to either filter-based FilterWire EX or balloon occlusion/aspiration GuardWire embolic protection devices. IIb/IIIa inhibitor use was at the discretion of the investigator, with randomization stratified by intended use. Patients pre-selected for IIb/IIIa inhibitor use(n=345) had higher baseline risk, with increased 30-day major adverse cardiac events(MACE, 13.0 vs. 8.0%, P=0.03). GuardWire assigned patients treated with IIb/IIIa inhibitors had higher 30-day MACE compared with those not treated with IIb/IIIa inhibitors(16.0 vs. 6.3%, P=0.007). In contrast, MACE in high-risk FilterWire patients treated with IIb/IIIa inhibitors were similar to their lower risk, untreated counterparts(9.9 vs. 9.5%, P=0.89). Multivariable analysis detected a borderline significant(P=0.056) interaction for lower MACE between FilterWire and IIb/ IIIa inhibitor use. Adjustment by the propensity to use IIb/IIIa inhibitors resulted in a significant(P=0.023) interaction for lower MACE rates. IIb/IIIa inhibition in conjunction with FilterWire was associated with less abrupt closure, no reflow, or distal embolization. Conclusion: IIb/IIIa antagonists may improve procedural outcome during SVG stenting in high risk patients, utilizing filter-based embolic protection devices.
Aims： Although embolic protection devices reduce complications during saphenous vein graft（SVG） stenting, adverse events still occur in -10% of patients. Ⅱb/Ⅲa antagonists have not been proven effective during SVG intervention. We hypothesized that adjunctive use of these agents might enhance the efficacy of embolic protection devices. Methods and results： In the prospective, multicentre FilterWire EX Randomized Evaluation trial, 651 patients undergoing SVG stenting were randomized to either filter-based FilterWire EX or balloon occlusion/aspiration GuardWire embolic protection devices. Ⅱb/Ⅲa inhibitor use was at the discretion of the investigator, with randomization stratified by intended use. Patients pre-selected for Ⅱb/Ⅲa inhibitor use（n = 345） had higher baseline risk, with increased 30-day major adverse cardiac events （MACE, 13.0 vs. 8.0%, P=0.03） . GuardWire assigned patients treated with Ⅱb/Ⅲa inhibitors had higher 30-day MACE compared with those not treated with Ⅱb/ Ⅲa inhibitors（16.0 vs. 6. 3%, P =0. 007）. In contrast, MACE in high-risk FilterWire patients treated with Ⅱb/Ⅲa inhibitors were similar to their lower risk, untreated counterparts（9.9 vs. 9.5%, P =0.89）. Multivariable analysis detected a borderline significant（P = 0. 056） interaction for lower MACE between FilterWire and Ⅱb/ Ⅲa inhibitor use. Adjustment by the propensity to use Ⅱb/Ⅲa inhibitors resulted in a significant （P = 0. 023） interaction for lower MACE rates.
